Literature DB >> 29862550

Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma.

Carrie A Thompson1, Kathleen J Yost2, Matthew J Maurer2, Cristine Allmer2, Umar Farooq3, Thomas M Habermann1, David J Inwards1, William R Macon4, Brian K Link3, Allison C Rosenthal5, James R Cerhan2.   

Abstract

Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overall survival (OS). QOL was measured with the Functional Assessment of Cancer Treatment-General (FACT-G), which measures 4 domains: physical, social/family, emotional, and functional well-being (WB); a single item Linear Analogue Self-Assessment (LASA) measuring overall QOL; and a spiritual WB LASA. From 9/2002 to 12/2009, 701 patients with aggressive lymphoma who completed baseline QOL questionnaires were enrolled. At a median follow-up of 71 months (range 6-128), 316 patients (45%) had an event and 228 patients (33%) died. All baseline QOL measures but emotional WB were significantly associated with OS (all P < 0.04); of which all but LASA spiritual remained significant after adjusting for IPI and NHL subtype. The strongest associations were with total FACT-G (adjusted HR = 0.86, 95% CI: 0.79-0.94, P = 0.00062) and functional WB (adjusted HR = 0.88, 95% CI: 0.83-0.93, P < .0001). QOL LASA was associated with OS (adjusted HR = 0.92, 95% CI: 0.87-0.97, P = 0.0041). Patients with clinically deficient QOL (overall QOL ≤50) had a median OS of 92 months compared with 121 months for patients with QOL >50 (P = 0.0004). In this large sample of patients with aggressive lymphoma, we found that baseline QOL is independently predictive of OS. QOL should be assessed as a prognostic factor in patients with aggressive lymphoma.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  lymphoma; prognosis; quality of life; surveys and questionnaires; survival

Mesh:

Year:  2018        PMID: 29862550      PMCID: PMC6402794          DOI: 10.1002/hon.2522

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  29 in total

1.  Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial.

Authors:  M Jerkeman; S Kaasa; M Hjermstad; S Kvaløy; E Cavallin-Stahl
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 2.  Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks.

Authors:  Jeff A Sloan; Lawrence Berk; Joseph Roscoe; Michael J Fisch; Edward G Shaw; Gwen Wyatt; Gary R Morrow; Amylou C Dueck
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

3.  Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice.

Authors:  Zeeshan Butt; Lynne I Wagner; Jennifer L Beaumont; Judith A Paice; Amy H Peterman; Dan Shevrin; Jamie H Von Roenn; George Carro; Joshua L Straus; J Cameron Muir; David Cella
Journal:  J Pain Symptom Manage       Date:  2007-10-23       Impact factor: 3.612

4.  Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Authors:  Chantal Quinten; Corneel Coens; Murielle Mauer; Sylvie Comte; Mirjam A G Sprangers; Charles Cleeland; David Osoba; Kristin Bjordal; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

5.  Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy.

Authors:  François Meyer; André Fortin; Michel Gélinas; Abdenour Nabid; François Brochet; Bernard Têtu; Isabelle Bairati
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

6.  Quality of life scores predict survival among patients with head and neck cancer.

Authors:  Carrie A Karvonen-Gutierrez; David L Ronis; Karen E Fowler; Jeffrey E Terrell; Stephen B Gruber; Sonia A Duffy
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

7.  Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma.

Authors:  Kathrin Strasser-Weippl; Heinz Ludwig
Journal:  Eur J Haematol       Date:  2008-07-11       Impact factor: 2.997

8.  Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients.

Authors:  Kerry S Courneya; Christopher M Sellar; Clare Stevinson; Margaret L McNeely; Carolyn J Peddle; Christine M Friedenreich; Keith Tankel; Sanraj Basi; Neil Chua; Alex Mazurek; Tony Reiman
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

9.  Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial.

Authors:  Barbara L Andersen; Hae-Chung Yang; William B Farrar; Deanna M Golden-Kreutz; Charles F Emery; Lisa M Thornton; Donn C Young; William E Carson
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

Review 10.  The prognostic significance of patient-reported outcomes in cancer clinical trials.

Authors:  Carolyn C Gotay; Crissy T Kawamoto; Andrew Bottomley; Fabio Efficace
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

View more
  6 in total

1.  Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Richard T Maziarz; Edmund K Waller; Ulrich Jaeger; Isabelle Fleury; Joseph McGuirk; Harald Holte; Samantha Jaglowski; Stephen J Schuster; Michael R Bishop; Jason R Westin; Stephan Mielke; Takanori Teshima; Veronika Bachanova; Stephen R Foley; Peter Borchmann; Gilles A Salles; Jie Zhang; Ranjan Tiwari; Lida B Pacaud; Qiufei Ma; Constantine S Tam
Journal:  Blood Adv       Date:  2020-02-25

2.  Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis.

Authors:  Christopher S Strouse; Melissa C Larson; Shawna L Ehlers; Kathleen J Yost; Matthew J Maurer; Stephen M Ansell; David J Inwards; Patrick B Johnston; Ivana N Micallef; Brian K Link; Umar Farooq; James R Cerhan; Carrie A Thompson
Journal:  JCO Oncol Pract       Date:  2022-05-20

Review 3.  Quality of Life and Survivorship in Lymphoma.

Authors:  Allison Rosenthal
Journal:  Curr Oncol Rep       Date:  2022-04-08       Impact factor: 5.945

4.  The association of health behaviors with quality of life in lymphoma survivors.

Authors:  Priyanka A Pophali; Melissa C Larson; Allison C Rosenthal; Dennis Robinson; Thomas M Habermann; Gita Thanarajasingam; Timothy Call; Cristine Allmer; Umar Farooq; Matthew J Maurer; Kathleen J Yost; James R Cerhan; Carrie A Thompson
Journal:  Leuk Lymphoma       Date:  2020-10-13

5.  A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.

Authors:  Hervé Ghesquières; Cédric Rossi; Fanny Cherblanc; Sandra Le Guyader-Peyrou; Fontanet Bijou; Pierre Sujobert; Pascale Fabbro-Peray; Adeline Bernier; Aurélien Belot; Loic Chartier; Luc-Matthieu Fornecker; Isabelle Baldi; Krimo Bouabdallah; Camille Laurent; Lucie Oberic; Nadine Morineau; Steven Le Gouill; Franck Morschhauser; Corinne Haioun; Gandhi Damaj; Stéphanie Guidez; Gaëlle Labouré; Olivier Fitoussi; Laure Lebras; Rémy Gressin; Gilles Salles; Loïc Ysebaert; Alain Monnereau
Journal:  BMC Public Health       Date:  2021-03-02       Impact factor: 3.295

6.  Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study.

Authors:  Rebecca Cheng; Kayla Scippa; Frederick L Locke; Julia Thornton Snider; Heather Jim
Journal:  Oncol Ther       Date:  2021-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.